Want to see PHAR full AI Analyst Report?
PHAR Stock Chart & Stats
$12.62
-$0.55(-4.21%)
At close: 4:00 PM EDT
$12.62
-$0.55(-4.21%)
Day’s Range― - ―
52-Week Range$9.62 - $21.34
Previous Close$12.62
Volume5.37K
Average Volume (3M)5.77K
Market Cap
$823.42M
Enterprise Value$1.08K
Total Cash (Recent Filing)$158.28M
Total Debt (Recent Filing)$113.30M
Price to Earnings (P/E)80.7
Beta0.47
Next Earnings
Nov 05, 2026EPS Estimate
0.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.14
Shares Outstanding70,778,120
10 Day Avg. Volume5,378
30 Day Avg. Volume5,772
Financial Highlights & Ratios
PEG Ratio-3.60
Price to Book (P/B)4.55
Price to Sales (P/S)3.35
P/FCF Ratio23.36
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$37.50Price Target Upside197.15% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)0.23
Revenue Forecast (FY)$390.63M
Bulls Say, Bears Say
Bulls Say
Joenja Growth And Market ExpansionJoenja is developing into a strong growth engine, supported by rising patient adoption, international launches and pediatric expansion. Continued geographic and label broadening can diversify revenue beyond RUCONEST and strengthen Pharming’s rare-disease franchise.
Broader Joenja Commercial OpportunityEU-wide authorization expands Pharming’s addressable market and gives Joenja first-mover status as the only approved APDS treatment there. This supports a broader commercial footprint, greater patient access and potentially more durable product revenue.
Manageable Leverage And Positive Cash GenerationA manageable debt burden and currently positive cash generation provide financial flexibility for commercialization and pipeline investment. Although consistency remains imperfect, cash-backed earnings reduce reliance on external financing over the next several quarters.
Bears Say
RUCONEST Pressure And Limited Top-line GrowthRUCONEST remains the larger established revenue base but faces competitive pressure, market withdrawals and inventory normalization. Its weakness has forced lower company guidance, limiting near-term growth while Joenja scales and increasing dependence on one growth product.
Volatile Cash ConversionRecent operating cash outflows and a declining cash balance show that funding capacity is sensitive to operating performance and working-capital movements. Continued pipeline spending could reduce flexibility if commercial cash generation does not become more consistent.
Thin Profitability Amid Elevated InvestmentPositive earnings have returned, but the thin net margin leaves limited room for revenue setbacks or cost inflation. Heavy R&D investment may support future growth, yet it pressures current profitability and raises execution risk before pipeline programs generate revenue.
Pharming Group News
PHAR FAQ
What was Pharming Group Nv’s price range in the past 12 months?
Pharming Group Nv lowest stock price was $9.62 and its highest was $21.34 in the past 12 months.
What is Pharming Group Nv’s market cap?
Pharming Group Nv’s market cap is $823.42M.
When is Pharming Group Nv’s upcoming earnings report date?
Pharming Group Nv’s upcoming earnings report date is Nov 05, 2026 which is in 75 days.
How were Pharming Group Nv’s earnings last quarter?
Pharming Group Nv released its earnings results on Jul 30, 2026. The company reported $0.02 earnings per share for the quarter, missing the consensus estimate of $0.063 by -$0.043.
Is Pharming Group Nv overvalued?
According to Wall Street analysts Pharming Group Nv’s price is currently Undervalued.
Does Pharming Group Nv pay dividends?
Pharming Group Nv does not currently pay dividends.
What is Pharming Group Nv’s EPS estimate?
Pharming Group Nv’s EPS estimate is 0.11.
How many shares outstanding does Pharming Group Nv have?
Pharming Group Nv has 70,778,120 shares outstanding.
What happened to Pharming Group Nv’s price movement after its last earnings report?
Pharming Group Nv reported an EPS of $0.02 in its last earnings report, missing expectations of $0.063. Following the earnings report the stock price went down -10.491%.
Which hedge fund is a major shareholder of Pharming Group Nv?
Currently, no hedge funds are holding shares in PHAR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Pharming Group Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$37.50 (197.15% Upside)
$37.50 (197.15% Upside)
Blogger Sentiment
Bullish
PHAR Sentiment 100%
Sector Average ―
Sector Average ―
Crowd Wisdom
Very Positive
Last 7 Days ▼ 2.0%
Last 30 Days ▲ 10.2%
Last 30 Days ▲ 10.2%
Technicals
SMA
Negative
20 days / 200 days
Momentum
26.83%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
4.87%
Trailing 12-Months
Company Description
Pharming Group Nv
Pharming Group N.V. is a biopharmaceutical company dedicated to the creation and commercialization of protein replacement therapies and precision medicines. The firm concentrates its efforts on addressing rare diseases and critical unmet medical needs across the United States, Europe, and other international markets. Its primary commercialized product is Ruconest, a recombinant human C1 esterase inhibitor utilized for the acute treatment of hereditary angioedema. Pharming's development pipeline also includes rhC1INH, which is being investigated for conditions such as pre-eclampsia, acute kidney injury, and COVID-19. Additionally, the company is developing leniolisib, a phosphoinositide 3-kinase delta (PI3K delta) inhibitor designed for patients with activated PI3K delta syndrome, as well as an alpha-glucosidase therapy targeting Pompe and Fabry diseases. The company has established significant collaborations, including a development and licensing agreement with Novartis. It also maintains a strategic partnership with Orchard Therapeutics plc for the research, development, manufacturing, and commercialization of OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy intended for hereditary angioedema. Pharming Group N.V. is headquartered in Leiden, the Netherlands.
PHAR Company Deck
PHAR Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presented a mixed picture: strong commercial momentum for Joenja (robust percentage growth, geographic and pediatric expansion) and encouraging underlying RUCONEST demand indicators (active patient base ~93%, sequential revenue rebound) are offset by near-term headwinds — RUCONEST year-over-year revenue declines, a $30M revenue guidance reduction, operating cash outflows, and a manufacturing inventory impairment. Management emphasized cost discipline, positive operating profit in Q2, sufficient cash to fund the pipeline, and several upcoming clinical catalysts (leniolisib Phase II readouts in Q4, napazimone in 2027) that could materially change the trajectory. Given the balance of meaningful near-term challenges against several concrete growth drivers and pipeline milestones, the overall tone is cautious and balanced.View all PHAR earnings summariesPHAR Stock 12 Month Forecast
Average Price Target
$37.50
▲(197.15% Upside)
Technical Analysis
Trevi Therapeutics
―
Oric Pharmaceuticals
―
Praxis Precision Medicines
―
ARS Pharmaceuticals
―
Prime Medicine, Inc.
―
Ownership Overview
―
Insiders
0.02% Mutual Funds
3.13% Other Institutional Investors
96.85% Public Companies and
Individual Investors